Bauer Noël J C, de Vries Niels E, Webers Carroll A B, Hendrikse Fred, Nuijts Rudy M M A
Department of Ophthalmology, Academic Hospital Maastricht, Debyelaan 25, Maastricht, The Netherlands.
J Cataract Refract Surg. 2008 Sep;34(9):1483-8. doi: 10.1016/j.jcrs.2008.05.031.
To present clinical data from a single-center prospective clinical trial of the AcrySof toric intraocular lens (IOL).
Academic Hospital Maastricht, Maastricht, The Netherlands.
Fifty-three eyes (43 patients) had implantation of an AcrySof toric IOL. Three toric models were evaluated in cylinder powers of 1.50 diopters (D) (SN60T3; T3 group, n = 16), 2.25 D (SN60T4; T4 group, n = 14), and 3.00 D (SN60T5; T5 group, n = 23) at the IOL plane. The T5 group was subdivided into eyes that could be fully corrected (T5a, n = 13) and eyes that could be partially corrected (T5b, n = 10).
Four months postoperatively, the mean uncorrected visual acuity (UCVA) was 0.77 +/- 0.23 in the T3 group, 0.93 +/- 0.23 in the T4 group, 0.82 +/- 0.15 in the T5a group, and 0.47 +/- 0.13 in the T5b group. More than 90% of the combined eyes in the T3, T4, and T5a groups achieved a UCVA of 20/40 or better, and almost 80% achieved a UCVA of 20/25 or better. Residual refractive astigmatism of less than 0.75 D was achieved in 74% of eyes and of less than 1.00 D in 91%. The mean IOL misalignment was 2.5 +/- 2.1 degrees in the T3 group, 3.5 +/- 2.3 degrees in the T4 group, and 4.1 +/- 3.5 degrees in the T5 group.
Implantation of the AcrySof toric IOL proved to be an effective, safe, and predictable method of managing corneal astigmatism in cataract patients.
展示一项关于AcrySof散光型人工晶状体（IOL）的单中心前瞻性临床试验的临床数据。
荷兰马斯特里赫特学术医院。
53只眼（43例患者）植入了AcrySof散光型IOL。在IOL平面评估了三种散光模型，柱镜度数分别为1.50屈光度（D）（SN60T3；T3组，n = 16）、2.25 D（SN60T4；T4组，n = 14）和3.00 D（SN60T5；T5组，n = 23）。T5组又分为可完全矫正的眼（T5a，n = 13）和可部分矫正的眼（T5b，n = 10）。
术后4个月，T3组的平均裸眼视力（UCVA）为0.77±0.23，T4组为0.93±0.23，T5a组为0.82±0.15，T5b组为0.47±0.13。T3、T4和T5a组中超过90%的联合眼UCVA达到20/40或更好，近80%达到20/25或更好。74%的眼残余屈光性散光小于0.75 D，91%小于1.00 D。T3组IOL平均偏心2.5±2.1度，T4组为3.5±2.3度，T5组为4.1±3.5度。
AcrySof散光型IOL植入术被证明是治疗白内障患者角膜散光的一种有效、安全且可预测的方法。
